Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYPOLAN: Cisplatin Doublets + Hypofractionated RT in NSCLC
NCT02947113Phase 2Withdrawn
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, pemetrexed and etoposide in non-small cell lung carcinoma (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoint: Incidence of treatment related Adverse events at 3 months. Planned start Nov 2017; status: withdrawn.
02
Drugs
cisplatinpemetrexedetoposide
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT02947113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947113.